Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single‐institution study
- 5 November 2014
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 16 (6) , 1032-1038
Abstract
The introduction of proteasome inhibitors and/or immunomodulators in the treatment of myeloma has led to an increase in viral infections, particularly in the Herpesviridae family. Previous studies about the risk of cytomegalovirus (CMV) reactivation after autologous stem cell transplantation (ASCT) have examined the clinical outcome after the first ASCT; however, only 1 study to date has investigated the risk of CMV reactivation after a second transplantation. To address this issue, we performed a retrospective chart review on 78 consecutive myeloma patients (median age 56 years) who underwent a tandem non‐CD34+ selected ASCT after induction treatment with either conventional chemotherapy (n = 42) or with novel agents (n = 36), respectively. All subjects had been mobilized and conditioned with cyclophosphamide plus granulocyte colony‐stimulating factor and melphalan alone, respectively. CMV DNA load in the blood has been determined by polymerase chain reaction in the case of a clinical suspicion of CMV reactivation; therefore, routine monitoring was not performed. Considering the outcome of both the first and the second transplantations, we observed a total of 13 episodes of symptomatic CMV reactivation (13/156, 8%), in 12 subjects (12/78, 15%), all successfully treated. Eight subjects experienced a CMV reactivation after the first ASCT (8/78, 10%); however, only 1 of them (1/8, 12%) experienced a CMV reactivation after the second transplantation. Conversely, 4 CMV reactivations (6%) were observed after the second transplantation in the group of 70 patients who did not experience a CMV reactivation after the first ASCT. No statistically significant difference was observed between first and second ASCT (8/78, 10% vs. 5/78, 6%; P = 0.767). Univariate analysis showed that a pre‐transplant treatment with novel agents was the only baseline factor significantly associated with the occurrence of post‐ASCT CMV symptomatic reactivation after the first transplant (odds ratio [OR]: 9.897; 95% confidence interval [CI]: 1.154–84.840; P = 0.021) but not after the second transplant (OR: 5.125; 95% CI: 0.546–48.119; P = 0.115). No end‐organ disease or primary infection was documented. Our data suggest that second transplantation does not increase the risk of CMV reactivation in our patient population, when compared with the first one, and confirm the role of a pre‐transplant treatment with novel agents as a risk factor for CMV symptomatic reactivation.Keywords
This publication has 30 references indexed in Scilit:
- Standard‐ versus high‐dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilizationTransfusion, 2010
- The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral InfectionThe Journal of Immunology, 2009
- Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel AgentsClinical Infectious Diseases, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years LaterJournal of Clinical Oncology, 2008
- Proteasome inhibition suppresses essential immune functions of human CD4+ T cellsImmunology, 2008
- Epidemiologic Analysis of Reactivated Cytomegalovirus Antigenemia in Patients with CancerJournal of Clinical Microbiology, 2007
- Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance programTransplant Infectious Disease, 2005
- Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSFBone Marrow Transplantation, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998